ARM has added another 7.3% this week to close at $223.15, capping a 34% gain over the past month, and the story has quietly shifted from post-earnings relief rally to something more sustained — and more contested.
The Street's re-rating continued this week. Bernstein initiated coverage on May 18 with an Outperform and a $300 target, the most bullish new entry in the cohort. That follows a wave of target hikes on May 7 — Barclays to $250, TD Cowen to $265, RBC to $260, Wells Fargo to $255, Keybanc to $300, and Evercore ISI to $326 — all maintaining positive ratings after the earnings beat. The consensus mean target now sits at $230.91, barely 3.5% above the current price. The implication is that, for most bulls, ARM has already largely covered the gap the Street opened up after the print. Goldman Sachs remains the lone Sell, with a $150 target — a level the stock traded above weeks ago and has since left further behind. The bull case rests on a 20% royalty revenue CAGR through fiscal 2031, accelerating Armv9 adoption, and a cloud AI addressable market bulls see growing from $330 billion to over $1.2 trillion. Goldman's counter is valuation: at 89x trailing earnings and 20x price-to-book, the multiple embeds an enormous amount of execution.
The factor data broadly supports the momentum story. Forward EPS growth ranks in the 91st percentile on a 12-month year-over-year basis, and 90-day EPS momentum sits at the 80th percentile. Analyst recommendation divergence ranks at the 88th percentile — a reflection of how wide the bull-bear gap has grown. The ORTEX short score has edged down slightly from a May 11 peak of 62.4 to 59.7, consistent with the note published here last week: the Goldman divergence remains the central structural tension, but it is not yet attracting a meaningful wave of fresh short capital.
Short positioning tells a genuinely unexciting story given the move. Estimated short interest has drifted slightly lower over the week, down about 0.75%, to roughly 16 million shares. The borrowing market is relaxed: cost to borrow is just 0.42%, and availability at 200% means there are roughly two shares available to lend for every one already out on loan — a comfortable, uncrowded borrow market. The put/call ratio at 1.14 is marginally below its 20-day average of 1.17, and the z-score of -0.58 indicates options positioning is if anything slightly less defensive than usual for this name. Short sellers are not pressing the bear case harder into strength — there is no technical squeeze pressure, no borrowing friction, and no options hedging spike.
Among correlated peers, the divergence this week is notable. MRVL gained 7.2% — essentially in lockstep with ARM — while MX added 9.4%. But RMBS dropped 6.3% and ACLS fell 11.4%, suggesting the chip sector is far from uniformly bid. ARM's gain looks more idiosyncratic to AI architecture licensing than a broad semiconductor tide.
The next earnings event is not until July 29. Between now and then, the key tension to watch is whether the consensus price target — now barely above spot — gets revised further upward fast enough to maintain a credible upside case, or whether the stock's multiple begins to look fully priced even against the most optimistic royalty ramp assumptions.
See the live data behind this article on ORTEX.
Open ARM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
